Clinical Trial Search

Primary: Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline — 1.1; .9 score on a scale

Primary: Change From Baseline in Clinician Interview-Based Assessment of Change Plus Caregiver Input (CIBIC-Plus) Global Score (New York Univeristy Version) — 2.3; 5.22 units on…

Primary: Change From Baseline in CSF Abeta42 — 4.8; 12.5; 16.2 pg/mL — p=0.087

Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)

Primary: Maximum Plasma Concentration (Cmax) — 1020; 1100 ng/mL

Primary: Change in Cognition — 0.64; 0.55; 1.27 units on a scale — p=1.000

Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819

Primary: Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF) — -0.4; 2.2 Units on a scale — p=0.001

Primary: Changes in the Metabolite Ratios of N-acetylaspartate (NAA) to Creatine (Cr), Myo-inositol (mI) to Cr, Choline (Cho) to Cr, NAA to Cho, and NAA to mI, on Cholinesterase…

Primary: Change in Cognition — 0.68; 0.13 units on a scale — p=0.2365

Primary: ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale — -.27; 0.19 score on scale - baseline to endpoint — p=<0.67

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 24; 24; 24; 24 Participants

Primary: Change in Cognition — 0.13; 0.47; 0.18 units on a scale — p=0.9591

Primary: Percent Change From Baseline to Week 12 Based on Hippocampus Connectivity Index (HCI) — 7.47 percent change

Primary: Safety: Treatment-emergent Adverse Events and Serious Adverse Events for All Randomized Subjects Who Received Any Study Medication — 15; 13; 4; 4 number of events

Primary: Event-related Potential (ERP) P300 Latency at Baseline — 361.5; 382.3; 375.3 Milliseconds (ms)

Primary: Alzheimer's Disease Cooperative Study- Clinical Global Impression Change (ADCS-CGIC) — 3.92; 3.48 scores on the CGIC

Primary: One-card Learning (OCL) Measurement Over 12 Weeks of Treatment — 0.954; 0.942; 0.822; 0.969 Score on a scale

Primary: Change From Baseline to Last Visit of Double-Blind Treatment Period in Cognitive Function as Measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale…

Primary: Global Statistical Test (GST) Score — -0.126; -0.208 Z-score

Primary: Change From Baseline to Week 78 in Neuropsychological Test Battery (NTB) Z-score (Full Analysis Set; FAS) — -0.383; -0.350 Scores on a Scale — p=0.71

Primary: Total and Delayed Recall on the Hopkins Verbal Learning Test - Revised (HVLT-R) — -0.09679; -0.15776 Z-score — p=0.564

Primary: Overall Summary of Adverse Events (AEs) — 67.65; 47.06; 7.06; 0.59 Percentage of participants

Primary: The Primary Outcome Measure is the Number of Subjects in Each Group Who Are Able to Pass the DriveABLE On-Road Test at Month 12 (Endpoint). — 13; 10; 13; 9 participants

Primary: Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs) — 97.2; 93.3; 90.0; 91.4 percentage of participants

Primary: ADAS-Cog-Exec Global Composite — -0.146; -0.068 Change score — p=0.29

Primary: Part 2: Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) — 91.5; 95.4; 24.8; 38.0 Percentage of Participants

Primary: Brain Glucose Consumption — 27.9; 28.1 umol/100 g/min

Primary: Number of Participants With Any Gastrointestinal (GI) Symptoms — 1; 1 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 9; 5; 10; 5 Participants